In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA-approved CRISPR-Cas9 gene editing treatment. The therapy—which involves removing blood stem ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

CRISPR is like an editor that can rewrite DNA letter by letter or gene by gene, to remove harmful mutations or add protective ...

A little over a year ago, the FDA approved Casgevy, a cellular therapy, for the treatment of sickle cell disease and beta-thalassemia. Vertex and CRISPR Therapeutics haven't started recording ...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can go ahead, after the FDA lifted a hold on a review. The companies had applied ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

Why are CRISPR companies not OK ... and the approval of a non-opioid pain drug from Vertex Pharmaceuticals. Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT ...

Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized ...